Trial Publication after Registration in ClinicalTrials.Gov: A Cross-Sectional Analysis
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: ClinicalTrials.gov is a publicly accessible, Internet-based registry of clinical trials managed by the US National Library of Medicine that has the potential to address selective trial publication. Our objectives were to examine completeness of registration within ClinicalTrials.gov and to determine the extent and correlates of selective publication. METHODS AND FINDINGS: We examined reporting of registration information among a cross-section of trials that had been registered at ClinicalTrials.gov after December 31, 1999 and updated as having been completed by June 8, 2007, excluding phase I trials. We then determined publication status among a random 10% subsample by searching MEDLINE using a systematic protocol, after excluding trials completed after December 31, 2005 to allow at least 2 y for publication following completion. Among the full sample of completed trials (n = 7,515), nearly 100% reported all data elements mandated by ClinicalTrials.gov, such as intervention and sponsorship. Optional data element reporting varied, with 53% reporting trial end date, 66% reporting primary outcome, and 87% reporting trial start date. Among the 10% subsample, less than half (311 of 677, 46%) of trials were published, among which 96 (31%) provided a citation within ClinicalTrials.gov of a publication describing trial results. Trials primarily sponsored by industry (40%, 144 of 357) were less likely to be published when compared with nonindustry/nongovernment sponsored trials (56%, 110 of 198; p<0.001), but there was no significant difference when compared with government sponsored trials (47%, 57 of 122; p = 0.22). Among trials that reported an end date, 75 of 123 (61%) completed prior to 2004, 50 of 96 (52%) completed during 2004, and 62 of 149 (42%) completed during 2005 were published (p = 0.006). CONCLUSIONS: Reporting of optional data elements varied and publication rates among completed trials registered within ClinicalTrials.gov were low. Without greater attention to reporting of all data elements, the potential for ClinicalTrials.gov to address selective publication of clinical trials will be limited. Please see later in the article for the Editors' Summary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trial registries are an important source of information for tracking clinical trials from their inception through to their reporting, and have been used to measure publication bias and outcome reporting bias.”
From Systematic review protocol assessing the processes for linking clinical trial registries and their published results (2016) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 2×
“Similarly unpublished clinical trials of rosiglitazone [3] identified from a company-maintained website and of erythropoiesis-stimulating agents [4] and antidepressants [5] found among data submitted to the FDA revealed important efficacy and safety information to be missing from the medical literature.”
BackgroundSelf-citationSilverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., et al. (2000) · JAMA · doi:10.1001/jama.284.10.1247 · Cited by 3,154
Publication bias in clinical research
Easterbrook, P. J., Gopalan, R., Berlin, J. A., & Matthews, D. R. (1991) · The Lancet · doi:10.1016/0140-6736(91)90201-y · Cited by 3,109 · cited 1×
“Many studies have attempted to evaluate the extent of selective publication in the biomedical literature and found similarly low rates of publication [5,12–24], although none have used, to our knowledge, as large and as broadly representative a registry as ClinicalTrials.”
BackgroundSelective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435 · cited 3×
“Similarly unpublished clinical trials of rosiglitazone [3] identified from a company-maintained website and of erythropoiesis-stimulating agents [4] and antidepressants [5] found among data submitted to the FDA revealed important efficacy and safety information to be missing from the medical literature.”
BackgroundResultPharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003) · BMJ · doi:10.1136/bmj.326.7400.1167 · Cited by 2,147 · cited 1×
“However, we also found significantly different publication rates among study types and primary sponsors, consistent with prior research [11].”
ResultChan, A.-W., Hróbjartsson, A., Haahr, M. T., Gøtzsche, P. C., & Altman, D. G. (2004) · JAMA · doi:10.1001/jama.291.20.2457 · Cited by 1,845 · cited 1×
“Given the documented presence of outcome reporting bias among trials studied in other settings [5,12,13], the potential impact of ClinicalTrials.”
ResultRisk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741 · cited 1×
“Other evidence concerning selective publication is anecdotal, such as the absence of 6 mo of trial data from a key publication describing the efficacy of celecoxib [25,26], the delay of publication for two early trials of rofecoxib until after the medication was withdrawn from the market [27–29], and the aforementione…”
BackgroundSystematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias
Dwan, K., Altman, D. G., Arnaiz, J. A., Bloom, J., Chan, A.-W., Cronin, E., Decullier, E., Easterbrook, P. J., Von Elm, E., Gamble, C., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003081 · Cited by 1,546 · cited 1×
“Many studies have attempted to evaluate the extent of selective publication in the biomedical literature and found similarly low rates of publication [5,12–24], although none have used, to our knowledge, as large and as broadly representative a registry as ClinicalTrials.”
BackgroundClinical Trial Registration: A Statement from the International Committee of Medical Journal Editors
De Angelis, C., Drazen, J. M., Frizelle, F. A., Haug, C., Hoey, J., Horton, R., Kotzin, S., Laine, C., Marusic, A., Overbeke, A. J. P. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejme048225 · Cited by 1,241
Dickersin, K. (1992) · JAMA · doi:10.1001/jama.1992.03480030052036 · Cited by 854
Cited by
Items 101–200 of 400
Differences between information in registries and articles did not influence publication acceptance
van Lent, M., IntHout, J., & Out, H. J. (2015) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2014.11.019 · Cited by 37
Clinical trial registration and reporting: a survey of academic organizations in the United States
Mayo-Wilson, E., Heyward, J., Keyes, A., Reynolds, J., White, S., Atri, N., Alexander, G. C., Omar, A., & Ford, D. E. (2018) · BMC Medicine · doi:10.1186/s12916-018-1042-6 · Cited by 43
van der Naald, M., Wenker, S., Doevendans, P. A., Wever, K. E., & Chamuleau, S. A. J. (2020) · BMJ Open Science · doi:10.1136/bmjos-2019-100051 · Cited by 40
Publication bias in clinical trials of electronic health records
Vawdrey, D. K., & Hripcsak, G. (2013) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2012.08.007 · Cited by 38
Publication of Sports Medicine–Related Randomized Controlled Trials Registered in ClinicalTrials.gov
Chahal, J., Tomescu, S. S., Ravi, B., Bach, B. R., Ogilvie-Harris, D., Mohamed, N. N., & Gandhi, R. (2012) · The American Journal of Sports Medicine · doi:10.1177/0363546512448363 · Cited by 38
“gov uses a Web-based system to facilitate clinical trial registration by any sponsor, principal investigator, or other person or organization with primary responsibility for the trial.(33) ClinicalTrials.”
MethodAll preclinical trials should be registered in advance in an online registry
Lorkeers, S. J. J. O., Doevendans, P. A., & Chamuleau, S. A. J. (2014) · European Journal of Clinical Investigation · doi:10.1111/eci.12299 · Cited by 39
Ranasinghe, I., Shojaee, A., Bikdeli, B., Gupta, A., Chen, R., Ross, J. S., Masoudi, F. A., Spertus, J. A., Nallamothu, B. K., & Krumholz, H. M. (2015) · Circulation · doi:10.1161/circulationaha.114.015080 · Cited by 40
Self-citationThe significance of the trial outcome was associated with publication rate and time to publication
Song, S. Y., Koo, D.-H., Jung, S.-Y., Kang, W., & Kim, E. Y. (2017) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2017.02.009 · Cited by 36
“5 A number of studies have previously addressed publi cation bias using various 6 methods and data sources such as assessing the publ ication of results using clinical trial 7 registries [8, 9, 17-22], research ethics committee s [23], the FDA database [24], and surveys 8 [7].”
BackgroundMethodZhao, S., Miao, M., Wang, Q., Zhao, H., Yang, H., & Wang, X. (2024) · BMC Cancer · doi:10.1186/s12885-023-11690-9 · Cited by 36
“The ClinicalTrials.gov database was frequently selected by other studies to characterize study populations and trends in clinical care and research [10, 11].”
MethodDelays in the Publication of Important Clinical Trial Findings in Oncology
Qunaj, L., Jain, R. H., Atoria, C. L., Gennarelli, R. L., Miller, J. E., & Bach, P. B. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0264 · Cited by 42
Mortberg, M. A., Vallabh, S. M., & Minikel, E. V. (2022) · Scientific Reports · doi:10.1038/s41598-022-21820-1 · Cited by 35
Trial Registration and Declaration of Registration by Authors of Randomized Controlled Trials
McGee, R. G., Su, M., Kelly, P. J., Higgins, G. Y., Craig, J. C., & Webster, A. C. (2011) · Transplantation · doi:10.1097/tp.0b013e318232baf2 · Cited by 34
“gov to facilitate the registration of clinical trials (4).”
BackgroundAdherence to guidance on registration of randomised controlled trials published in Anaesthesia
El‐Boghdadly, K., Wiles, M. D., Atton, S., & Bailey, C. R. (2018) · Anaesthesia · doi:10.1111/anae.14103 · Cited by 33
“[20] found that 46% of a sample of studies registered at ClinicalTrials.”
BackgroundSu, C.-X., Han, M., Ren, J., Li, W.-Y., Yue, S.-J., Hao, Y.-F., & Liu, J.-P. (2015) · Trials · doi:10.1186/s13063-014-0545-5 · Cited by 34
“Many empirical studies evaluating the consistency concerning outcomes between the protocol or trial registry entry of randomized clinical trials (RCTs) and subsequent publications have demonstrated that outcome reporting bias is prevalent and favors statistically significant results [9-16].”
BackgroundBattisti, N. M. L., Sehovic, M., & Extermann, M. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.03.005 · Cited by 35
Time to publication for results of clinical trials
Showell, M. G., Cole, S., Clarke, M. J., DeVito, N., Farquhar, C. M., & Jordan, V. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000011.pub3 · Cited by 57
Ross, J. S. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0334-1 · Cited by 37
Self-citationAl-Durra, M., Nolan, R. P., Seto, E., Cafazzo, J. A., & Eysenbach, G. (2018) · Journal of Medical Internet Research · doi:10.2196/11924 · Cited by 32
“%] and 393 [70.7%], respectively).”
InfluentialComparison of Arthroplasty Trial Publications After Registration in ClinicalTrials.gov
Smith, H. N., Bhandari, M., Mahomed, N. N., Jan, M., & Gandhi, R. (2012) · The Journal of Arthroplasty · doi:10.1016/j.arth.2011.11.005 · Cited by 34
“A study reviewing a random subsample of trials registered in CTG found that 40% of industry-sponsored trials were published in comparison with 56% of nonindustry- or nongovernment-sponsored trials and 47% of government-sponsored trials [37].”
ResultBourgeois, F. T., Olson, K. L., Tse, T., Ioannidis, J. P. A., & Mandl, K. D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155948 · Cited by 33
Jones, C. W., Braz, V. A., McBride, S. M., Roberts, B. W., & Platts‐Mills, T. F. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-013649 · Cited by 31
REVIEW OF NATURAL PRODUCTS ON PARKINSON’S DISEASE PATHOLOGY
Essa, M. M., Braidy, N., Bridge, W. J., Subash, S., Manivasagam, T., Vijayan, R. K., Al‐Adawi, S., & Guillemin, G. J. (2014) · Journal of Aging Research and Lifestyle · doi:10.14283/jarcp.2014.23 · Cited by 40
Khan, N. A., Singh, M., Spencer, H. J., & Torralba, K. D. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38784 · Cited by 35
“Although trial registration may potentially improve transparency in conduct and dissemination of results, its usefulness is limited by the lack of an absolute requirement to complete and update optional data elements, and to include complete protocols and results (12,33,39).”
BackgroundResultInfluentialGartlehner, G., Emprechtinger, R., Hackl, M., Jutz, F., Gartlehner, J. E., Nonninger, J.-N., Klerings, I., & Dobrescu, A. I. (2022) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2021-111846 · Cited by 33
Thelwall, M. A., & Kousha, K. (2016) · Scientometrics · doi:10.1007/s11192-016-2112-1 · Cited by 35
“gov contains information about a large number of public and commercial trials (Califf et al. 2012; Hirsch et al. 2013; Ross et al. 2009; Stockmann et al. 2014; Zarin et al. 2005, 2011)”
BackgroundBaudart, M., Ravaud, P., Baron, G., Dechartres, A., Haneef, R., & Boutron, I. (2016) · BMC Medicine · doi:10.1186/s12916-016-0551-4 · Cited by 32
“Lack of or delayed publication could be related to the lack of incentives to disseminate negative results, time constraints, limited resources, changing interests, or difficulties and failure to have the results published [34].”
BackgroundCanestaro, W. J., Hendrix, N., Bansal, A., Sullivan, S. D., Devine, E. B., & Carlson, J. J. (2017) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2017.08.004 · Cited by 32
van der Steen, J. T., van den Bogert, C. A., van Soest‐Poortvliet, M. C., FARSANI, S. F. F., Otten, R. H. J., ter Riet, G., & Bouter, L. M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0188247 · Cited by 32
Evaluation of Systematic Reviews of Interventions for Retina and Vitreous Conditions
Lê, J. T., Qureshı, R., Twose, C., Rosman, L. M., Han, G., Fapohunda, K., Saldanha, I. J., Scherer, R. W., Lum, F., Al‐Rajhi, A. A., et al. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2019.4016 · Cited by 29
Infrequent and incomplete registration of test accuracy studies: analysis of recent study reports
Korevaar, D. A., Bossuyt, P. M. M., & Hooft, L. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-004596 · Cited by 27
Time to publication of oncology trials and why some trials are never published
Chapman, P. B., Liu, N. J., Zhou, Q. C., Iasonos, A. E., Hanley, S., Bosl, G. J., & Spriggs, D. R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184025 · Cited by 34
van Valkenhoef, G., Loane, R. F., & Zarin, D. A. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0283-8 · Cited by 28
Open access to research data: the two sides of the coin
Hert, S. G. D., & Samama, C. M. (2016) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000000529 · Cited by 27
Precision and negative predictive value of links between ClinicalTrials.gov and PubMed.
Huser, V., & Cimino, J. J. (2012) · PubMed Central · Cited by 27
Wallach, J. D., Luxkaranayagam, A. T., Dhruva, S. S., Miller, J. E., & Ross, J. S. (2019) · BMC Medicine · doi:10.1186/s12916-019-1344-3 · Cited by 27
Self-citationCan We Depend on Investigators to Identify and Register Randomized Controlled Trials?
Scherer, R. W., Sieving, P. C., Ervin, A., & Dickersin, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044183 · Cited by 26
“, study design, protocol and contact information) are less than optimal for inclusion in systematic reviews [10,15,16,17].”
Backgroundvan Heteren, J. A. A., van Beurden, I., Peters, J. P. M., Smit, A. L., & Stegeman, I. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219458 · Cited by 29
Alayche, M., Cobey, K. D., Ng, J. Y., Ardern, C. L., Khan, K., Chan, A., Chow, R., Masalkhi, M., Ayala, A. P., Ebrahimzadeh, S., et al. (2023) · FACETS · doi:10.1139/facets-2022-0208 · Cited by 29
Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe?
Tranter, E., Peters, G., Boyce, M. J., & Warrington, S. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12096 · Cited by 26
Comparative Effectiveness Research: An Empirical Study of Trials Registered in ClinicalTrials.gov
Bourgeois, F. T., Murthy, S., & Mandl, K. D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0028820 · Cited by 26
“gov, which is the primary registry employed by investigators in the United States and which has previously been used to define and study large trial cohorts.[12,13] To begin to anticipate the impact of the investment in CE research, we determine the prevalence of CE research to date, the types of interventions studied…”
Jones, P. M. (2016) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-016-0632-z · Cited by 27
“gov were published two years after completion.(9) It is probable that at least some of the clinical trials remained unpublished due to negative results.”
BackgroundPublication status of contemporary oncology randomised controlled trials worldwide
Chen, Y., Liu, X., Lv, J.-W., Li, W., Zhang, Y., Guo, Y. Q., Lin, A.-H., Sun, Y. H., Mao, Y., & Ma, J. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.010 · Cited by 25
“A cross-sectional study evaluating trials completed before December 2005 reported that 70% of the published articles were positive [8], whereas 56% of the published trials in our study reported positive primary outcomes.”
BackgroundMethodNetwork meta-analyses performed by contracting companies and commissioned by industry
Schuit, E., & Ioannidis, J. P. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0377-3 · Cited by 24
Does open data boost journal impact: evidence from Chinese economics
Zhang, L., & Ma, L. (2021) · Scientometrics · doi:10.1007/s11192-021-03897-z · Cited by 24
Industrializing AI-powered drug discovery: lessons learned from the Patrimony computing platform
Guedj, M., Swindle, J., Hamon, A., Hubert, S., Desvaux, E., Laplume, J., Xuereb, L., Lefèbvre, C., Haudry, Y., Gabarroca, C., et al. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2095368 · Cited by 32
Clinical Research in Surgical Oncology: An Analysis of ClinicalTrials.gov
Menezes, A. S., Barnes, A., Scheer, A. S., Martel, G., Moloo, H., Boushey, R. P., Sabri, E., & Auer, R. C. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3054-y · Cited by 23
Availability of results from clinical research: Failing policy efforts
Shamliyan, T., & Kane, R. L. (2013) · Journal of Epidemiology and Global Health · doi:10.1016/j.jegh.2013.08.002 · Cited by 25
“These results are in concordance with previously published studies confirming that the results are not available for the public from the majority of clinical research [17,21,25].”
Publication and Dissemination of Results in Clinical Trials of Neurology
Sreekrishnan, A., Mampre, D. M., Ormseth, C. H., Miyares, L. C., Leasure, A. C., Ross, J. S., & Sheth, K. N. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0674 · Cited by 23
Self-citationSaito, A., Ishikawa, S., Yang, K., Sawa, A., & Ishizuka, K. (2025) · Journal of Nutritional Science · doi:10.1017/jns.2025.10033 · Cited by 26
“This percentage is consistent with the broader issue that only 46% of registered clinical trials are eventually published (67) .”
Zippel, C., & Bohnet-Joschko, S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18105072 · Cited by 25
“, published in 2009, showed a proportion of 40% in studies with industry sponsors [38] and a study by Bell and Smith from 2014 on over 24 thousand clinical studies on rare and non-rare conditions showed a proportion of more than 30 percent [42].”
BackgroundMethodThe Impact of Industry Funding on Randomized Controlled Trials of Biologic Therapies
Gazendam, A., Slawaska‐Eng, D., Nucci, N. W., Bhatt, O., & Ghert, M. A. (2022) · Medicines · doi:10.3390/medicines9030018 · Cited by 34
Long, J., Liang, R., Zheng, Q., Yuan, G., Xin, Z., Chen, X., Lai, F., & Liu, Y. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s288065 · Cited by 24
Timely and Complete Publication of Economic Evaluations Alongside Randomized Controlled Trials
Thorn, J. C., Noble, S., & Hollingworth, W. (2012) · PharmacoEconomics · doi:10.1007/s40273-012-0004-7 · Cited by 22
Underreporting of Research Biopsies from Clinical Trials in Oncology
Parseghian, C. M., Raghav, K. P. S., Wolff, R. A., Ensor, J., Yao, J. C., Ellis, L. M., Tam, A. L., & Overman, M. J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1449 · Cited by 22
Krleža-Jerić, K., Lemmens, T., Revéiz, L., Cuervo, L. G., & Bero, L. A. (2011) · PubMed · Cited by 27
Sharma, T., Guski, L. S., Freund, N., Meng, D. M., & Gøtzsche, P. C. (2019) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-195041 · Cited by 24
“Only about half of all studies presented as abstracts are subsequently published [1] and trials primarily sponsored by industry are less likely to be published than non-industry/non-government sponsored trials (risk ratio [RR] = 0.73, 95% confidence interval [CI] 0.61 to 0.87) [2].”
InfluentialDrug Approval and Drug Effectiveness
Spielmans, G. I., & Kirsch, I. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185533 · Cited by 23
“F or p er so na l u se o nl y. CP10CH27-Spielmans ARI 11 February 2014 12:21 inquire about the publication status of studies that were apparently unpublished, their requests went unanswered 62% of the time (Ross et al. 2009).”
BackgroundIt's Time for AllTrials Registered and Reported
Brown, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.ed000057 · Cited by 21
Potthast, R., Vervölgyi, V., McGauran, N., Kerekes, M. F., Wieseler, B., & Kaiser, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092067 · Cited by 20
“gov and completed prior to January 2006 were published 2 years after completion [45].”
BackgroundA web-based tool for automatically linking clinical trials to their publications
Smalheiser, N. R., & Holt, A. W. (2022) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocab290 · Cited by 20
Pang, W. K., Yeter, K. C., Torralba, K. D., Spencer, H. J., & Khan, N. A. (2015) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.12607 · Cited by 21
Clinical research in cancer palliative care: a metaresearch analysis
Vinches, M., Neven, A., Fenwarth, L., Terada, M., Rossi, G., Kelly, S. M., Péron, J., Thomaso, M., Grøenvold, M., & de Rojas, T. (2020) · BMJ Supportive & Palliative Care · doi:10.1136/bmjspcare-2019-002086 · Cited by 21
Publication of Results of Registered Trials With Published Study Protocols, 2011-2022
Vorland, C. J., Brown, A. W., Kilicoglu, H., Ying, X., & Mayo‐Wilson, E. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.50688 · Cited by 27
Portalupi, S., von Elm, E. B., Schmucker, C. M., Lang, B., Motschall, E., Schwarzer, G., Gross, I. T., Scherer, R. W., Bassler, D., & Meerpohl, J. J. (2013) · Systematic Reviews · doi:10.1186/2046-4053-2-2 · Cited by 22
Arnberg, F. K., Alaie, I., Parling, T., & Jonsson, U. (2013) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2013.08.019 · Cited by 20
“Nevertheless, the findings herein represent trials that have passed the peer-review process and may thus reflect higher quality trials [43].”
ResultLampert, A., Hoffmann, G. F., & Ries, M. (2016) · PLOS ONE · doi:10.1371/journal.pone.0144973 · Cited by 19
Jones, C. W., Misemer, B. S., Platts‐Mills, T. F., Ahn, R., Woodbridge, A., Abraham, A., Saba, S., Korenstein, D. R., Madden, E., & Keyhani, S. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-019831 · Cited by 20
“Unable to determine significance of outcome change 4 (18) 1 (20)”
BackgroundPublication of Randomized Clinical Trials in Pediatric Research: A Follow-up Study
Crockett, L. K., Okoli, G. N., Neilson, C. J., Rabbani, R., Abou-Setta, A. M., & Klassen, T. P. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.0156 · Cited by 20
Zhang, L., & Ma, L. (2023) · Scientometrics · doi:10.1007/s11192-023-04684-8 · Cited by 19
Why should clinical trials be registered?
Wager, E., & Elia, N. (2014) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000000084 · Cited by 19
Kosa, S. D., Mbuagbaw, L. C. E., Debono, V. B., Bhandari, M., Dennis, B. B., Ene, G. E. V., Leenus, A., Shi, D., Thabane, M., Valvasori, S., et al. (2017) · Contemporary Clinical Trials · doi:10.1016/j.cct.2017.12.011 · Cited by 21
Principles of Designing a Clinical Trial: Optimizing Chances of Trial Success
El-Hagrassy, M. M., Duarte, D. G. G., Thibaut, A., Lucena, M. F. G., & Fregni, F. (2018) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-018-0152-y · Cited by 18
White, R., Peng, T., Sripitak, P., Johansen, A. R., & Snyder, M. P. (2023) · International Conference on Information Technology for Social Good (GoodIT) · doi:10.1145/3582515.3609559 · Cited by 28
“Reasons for not publishing vary from publication bias, commercial interest, to lack of significance [23].”
BackgroundPansieri, C., Pandolfini, C., & Bonati, M. R. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1897-9 · Cited by 21
Pharmacokinetic research in children: an analysis of registered records of clinical trials
Viergever, R. F., Rademaker, C. M. A., & Ghersi, D. (2011) · BMJ Open · doi:10.1136/bmjopen-2011-000221 · Cited by 19
Papageorgiou, S. N., Antonoglou, G. N., Sándor, G. K., & Eliades, T. (2017) · PLOS ONE · doi:10.1371/journal.pone.0182785 · Cited by 17
Not Reporting Results of a Clinical Trial Is Academic Misconduct
Wallach, J. D., & Krumholz, H. M. (2019) · Annals of Internal Medicine · doi:10.7326/m19-1273 · Cited by 18
Self-citationHolst, M., Haslberger, M., Yerunkar, S. S., Strech, D., Hemkens, L. G., & Carlisle, B. G. (2023) · PLoS Medicine · doi:10.1371/journal.pmed.1004306 · Cited by 19
A large-scale database for clinical trial outcomes and features
Gao, C., Pradeepkumar, J., Das, T., Thati, S., & Sun, J. (2026) · Nature Health · doi:10.1038/s44360-026-00081-6 · Cited by 20
Publication Delay of Randomized Trials on 2009 Influenza A (H1N1) Vaccination
Ioannidis, J. P. A., Manzoli, L., Vito, C. D., D’Addario, M., & Villari, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028346 · Cited by 17
“Only 42% of an unselected sample of trials completed in 2005 had been published by the end of 2007 [14].”
Backgroundde la Iglesia, D., García-Remesal, M., Anguita, A., Muñoz-Mármol, M., Kulikowski, C. A., & Maojo, V. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110331 · Cited by 21
“A number of articles have analyzed published trial results in terms of quality and completeness [8,9], as well as the impact of the public release of CTs [10–12], but these and other studies have not yet made, to our knowledge, such a clear distinction between nano and non-nano categories either.”
BackgroundGlass, H. E., Glass, L. M., & DiFrancesco, J. J. (2014) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479014551643 · Cited by 17
The Inclusion of Economic Endpoints as Outcomes in Clinical Trials Reported to ClinicalTrials.gov
Mitchell, J. M., & Patterson, J. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.4.386 · Cited by 17
Axson, S. A., Mello, M. M., Lincow, D., Yang, C. F., Gross, C. P., Ross, J. S., & Miller, J. E. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-053248 · Cited by 20
Self-citationAgha, R., & Rosin, D. (2015) · International Journal of Surgery · doi:10.1016/j.ijsu.2015.03.001 · Cited by 20
Re-Analyzing Phase III Bremelanotide Trials for “Hypoactive Sexual Desire Disorder” in Women
Spielmans, G. I. (2021) · The Journal of Sex Research · doi:10.1080/00224499.2021.1885601 · Cited by 17
Time to publication for publicly funded clinical trials in Australia: an observational study
Strand, L. B., Clarke, P., Graves, N., & Barnett, A. G. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-012212 · Cited by 17
Why clinical trials are terminatedPreprint
Pak, T. R., Rodriguez, M., & Roth, F. P. (2015) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/021543 · Cited by 19
Saesen, R., Lacombe, D. A., & Huys, I. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.04.012 · Cited by 15
Biases in the Evaluation of Psychiatric Clinical Evidence
Makhinson, M. (2011) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0b013e31823e62cd · Cited by 15
“gov), although recent analyses still demonstrate selective publication of registered trials (Bourgeois et al., 2010; Ross et al., 2009), suggesting that need for increased efforts to curb this practice.”
BackgroundWildt, S., Krag, A., & Gluud, L. (2011) · BMJ Open · doi:10.1136/bmjopen-2011-000309 · Cited by 15
Zou, Z., Ли, Б., Wen, S., Lin, D., Hu, Q., Wang, Z., & Fang, J. (2022) · Cancer Control · doi:10.1177/10732748221080348 · Cited by 16
Agha, R., & Rosin, D. (2015) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2015.03.001 · Cited by 14
“gov, just 46% of those that had completed by 2005 were published by 2007 [4].”
Rawal, B., & Deane, B. R. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.860371 · Cited by 18
Characteristics of NIH- and industry-sponsored head and neck cancer clinical trials
Devaiah, A. K., & Murchison, C. (2016) · The Laryngoscope · doi:10.1002/lary.25942 · Cited by 14
“Results Reporting We found no significant difference between the rates of publication in NIH-sponsored versus industrysponsored trials (Table II), in contrast to previous studies.(19) Publications from industry-sponsored trials had a significantly higher rate of positive results than NIHsponsored trials.”
ResultFredrickson, M. J., & Ilfeld, B. M. (2011) · Regional Anesthesia & Pain Medicine · doi:10.1097/aap.0b013e318230fbc4 · Cited by 15
“gov, only an estimated two thirds reported their primary outcome.(9)”
BackgroundRegistered Randomized Trials Comparing Generic and Brand-Name Drugs: A Survey
Flacco, M. E., Manzoli, L., Boccia, S., Puggina, A., Rosso, A., Marzuillo, C., Scaioli, G., Gualano, M. R., Ricciardi, W., Villari, P., et al. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.04.032 · Cited by 17
Hall, S. F., Liu, F., O’Sullivan, B., Shi, W., Rohland, S. L., Griffiths, R., & Groome, P. A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.275 · Cited by 14
“Ross et al (2015) assessed the publication rates of registered clinical trials at ClinicalTrials.gov after 31 December 1999 that were to be completed by 31 December 2005 and those that were documented as completed by 30 June 2007.”
BackgroundSo, D. F., Joly, Y., & Knoppers, B. M. (2013) · Public Health Genomics · doi:10.1159/000355941 · Cited by 14
Publicly funded practice-oriented clinical trials: of importance for healthcare payers
Neyt, M., Christiaens, T., Demotes‐Mainard, J., Walley, T., & Hulstaert, F. (2016) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2016-0018 · Cited by 14
Metadata
- Authors
- Ross, J. S., Mulvey, G. K., Hines, E. M., Nissen, S. E., & Krumholz, H. M.
- Affiliations
- Health Services Research & Development (US)
- Yale New Haven Hospital (US)
- Amherst College (US)
- Cleveland Clinic (US)
- Corresponding author
- Ross, Joseph S.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-09-08
- Volume
- 6
- Issue
- 9
- Pages
- e1000144
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC2728480
- OpenAlex
- W1970223153
- Cited by
- 401
- References
- 31
- Citations by year
- 2026: 17 · 2025: 10 · 2024: 15 · 2023: 10 · 2022: 16 · 2021: 20 · 2020: 18 · 2019: 14 · 2018: 23 · 2017: 27 · 2016: 38 · 2015: 39 · 2014: 36 · 2013: 35 · 2012: 32
- FWCI
- 24.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- U.S. Department of Veterans Affairs (K08 AG032886)
- Hartford Foundation for Public Giving
- Amgen
- Eli Lilly and Company
- Pfizer
- Sanofi
- Health Services Research and Development
- Cleveland Clinic
- Massachusetts Medical Society
- Daiichi-Sankyo
- Novo Nordisk
- National Institute on Aging (K08AG032886)
- U.S. National Library of Medicine
- Topics
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Social Sciences › Library and Information Sciences › Academic Publishing and Open Access
- Keywords
- ClinicalTrials.gov, clinical trial registration, selective publication, publication bias, registration completeness, industry funding, publication rates, clinical trial registries, primary outcome reporting
- MeSH terms
- Clinical Trials as Topic, Cross-Sectional Studies, Drug Industry, Financing, Government, Humans, National Library of Medicine (U.S.), Periodicals as Topic, Publishing, Registries, United States, Bibliometrics, Databases, Factual, Treatment Outcome, Internet, Information Dissemination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
